CAV2 and fragile X syndrome: Controlling functional expression of CaV is currently under intensive study as it represents a potential therapy for many neurological diseases (Dolphin, 2018; Zamponi, 2016) and our findings suggest that it could also be a potential new avenue to restore proper synaptic plasticity and neural networks during early neural development in a context of FXS.